Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

ClinicalTrials.gov ID: NCT04491942

Public ClinicalTrials.gov record NCT04491942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 22, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma

Study identification

NCT ID: NCT04491942
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 74 participants

Conditions and interventions

Conditions

Interventions

Cisplatin Drug
Elimusertib Drug
Gemcitabine Hydrochloride Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 24, 2021
Primary completion: Jun 29, 2026
Completion: Jun 29, 2026
Last update posted: Apr 12, 2026

2021 – 2026

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	—
National Cancer Institute Developmental Therapeutics Clinic	Bethesda	Maryland	20892	—
National Institutes of Health Clinical Center	Bethesda	Maryland	20892	—
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York	New York	10032	—
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	—
University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania	15232	—
University of Wisconsin Carbone Cancer Center - University Hospital	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04491942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced Apr 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04491942 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →